Human medicines European public assessment report (EPAR): Pravafenix, fenofibrate,pravastatin, Dyslipidemias, Date of authorisation: 14/04/2011, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Tecartus, Brexucabtagene autoleucel, Lymphoma, Mantle-Cell, Date of authorisation: 14/12/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Orserdu, elacestrant, Breast Neoplasms, Date of authorisation: 15/09/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Triumeq, abacavir sulfate / dolutegravir sodium / lamivudine, HIV Infections, Date of authorisation: 31/08/2014, Revision: 32, Status: Authorised

Triumeq-H-C-PSUSA-00010075-202301 : EPAR Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Prostatic Neoplasms, Castration-Resistant, Date of authorisation: 09/12/2022, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Pneumococcal Infections;Immunization, Date of authorisation: 09/12/2009, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Kivexa, abacavir,lamivudine, HIV Infections, Date of authorisation: 16/12/2004, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Apexxnar, pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Pneumococcal Infections, Date of authorisation: 14/02/2022, Revision: 6, Status: Authorised

Kivexa-H-C-PSUSA-00000011-202212 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation